In Cruel Move, Trump Reverses Medicare and Medicaid Coverage of Obesity Drugs

April 4, 2025

In Cruel Move, Trump Reverses Medicare and Medicaid Coverage of Obesity Drugs

WASHINGTON, D.C. - The Trump administration has reversed a Biden-era decision to give millions of Americans in need access to obesity drugs through Medicare and Medicaid.

In response, Dr. Robert Steinbrook, Director of Public Citizen's Health Research Group, issued the following statement:

"Medicare and Medicaid should cover GLP-1 drugs as medically needed. The Centers for Medicare and Medicaid Services should be taking bold action to bring down the price of these drugs by taking on Big Pharma. The CMS decision should lead to prompt price negotiations and expanded coverage of these important drugs. Instead, this decision takes us in the wrong direction, and continues to deny important medicines to many people who would benefit, based solely on their ability to pay for them."